Fig. 1From: Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft modelsExperimental protocol of this study. The left panel shows the ex vivo study with control (non-treatment) and two eribulin treatment (A, 0.3 and B, 1.0Â mg/kg) groups. The right panel shows PET imaging study with control (non-treatment) and eribulin treatment (0.3Â mg/kg) groupsBack to article page